Beijing Bohui Innovation Biotechnology Group Co., Ltd. Logo

Beijing Bohui Innovation Biotechnology Group Co., Ltd.

300318.SZ

(1.0)
Stock Price

5,81 CNY

-0.11% ROA

-0.23% ROE

-1692.64x PER

Market Cap.

5.448.723.000,00 CNY

69.54% DER

0% Yield

-0.32% NPM

Beijing Bohui Innovation Biotechnology Group Co., Ltd. Stock Analysis

Beijing Bohui Innovation Biotechnology Group Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock maintains a fair debt to equity ratio (60%), indicating a reasonable balance between the money it owes and the ownership it possesses.

2 Revenue Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

3 Net Profit Growth

This company's net profit has consistently grown over the past three years, showcasing a positive financial trend and making it an appealing investment opportunity.

4 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (788), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

5 ROE

The stock's ROE indicates a negative return (-3.79%) on shareholders' equity, suggesting poor financial performance.

6 ROA

The stock's ROA (-1.94%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

7 PBV

The stock's elevated P/BV ratio (3.77x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

10 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

11 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Beijing Bohui Innovation Biotechnology Group Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. Revenue
Year Revenue Growth
2004 24.509.852
2005 25.875.880 5.28%
2006 29.366.271 11.89%
2007 39.398.137 25.46%
2008 51.462.663 23.44%
2009 63.583.368 19.06%
2010 78.406.660 18.91%
2011 98.121.947 20.09%
2012 113.760.681 13.75%
2013 106.870.485 -6.45%
2014 100.969.495 -5.84%
2015 268.846.009 62.44%
2016 404.048.600 33.46%
2017 443.754.419 8.95%
2018 622.093.848 28.67%
2019 628.340.031 0.99%
2020 738.717.388 14.94%
2021 714.748.462 -3.35%
2022 795.932.495 10.2%
2023 1.116.767.694 28.73%
2023 1.045.429.099 -6.82%
2024 899.350.192 -16.24%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2004 0
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 5.223.249 100%
2010 7.209.400 27.55%
2011 8.330.054 13.45%
2012 11.236.531 25.87%
2013 11.888.611 5.48%
2014 21.360.672 44.34%
2015 35.522.299 39.87%
2016 40.537.269 12.37%
2017 48.513.085 16.44%
2018 53.456.738 9.25%
2019 46.577.177 -14.77%
2020 48.177.904 3.32%
2021 81.481.137 40.87%
2022 64.780.337 -25.78%
2023 96.539.334 32.9%
2023 69.202.812 -39.5%
2024 64.432.196 -7.4%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2004 3.947.254
2005 4.055.750 2.68%
2006 5.138.832 21.08%
2007 6.023.038 14.68%
2008 10.450.265 42.36%
2009 2.300.768 -354.21%
2010 2.028.713 -13.41%
2011 1.961.790 -3.41%
2012 4.015.975 51.15%
2013 3.283.298 -22.32%
2014 5.205.342 36.92%
2015 16.117.915 67.7%
2016 10.598.183 -52.08%
2017 21.430.953 50.55%
2018 25.292.400 15.27%
2019 26.211.036 3.5%
2020 41.732.853 37.19%
2021 71.473.947 41.61%
2022 40.645.654 -75.85%
2023 414.442.743 90.19%
2023 77.674.991 -433.56%
2024 -26.911.799 388.63%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. EBITDA
Year EBITDA Growth
2004 11.273.250
2005 12.099.335 6.83%
2006 13.820.985 12.46%
2007 18.826.597 26.59%
2008 22.497.323 16.32%
2009 30.129.378 25.33%
2010 39.422.004 23.57%
2011 52.738.861 25.25%
2012 58.254.359 9.47%
2013 51.323.919 -13.5%
2014 30.464.322 -68.47%
2015 44.604.835 31.7%
2016 98.072.129 54.52%
2017 95.780.695 -2.39%
2018 477.916.634 79.96%
2019 129.082.513 -270.24%
2020 132.687.524 2.72%
2021 11.832.312 -1021.4%
2022 11.194.485 -5.7%
2023 97.156.515 88.48%
2023 185.540.559 47.64%
2024 108.413.060 -71.14%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. Gross Profit
Year Gross Profit Growth
2004 19.204.297
2005 19.956.099 3.77%
2006 23.174.197 13.89%
2007 29.668.182 21.89%
2008 39.514.434 24.92%
2009 49.036.822 19.42%
2010 61.785.135 20.63%
2011 75.492.614 18.16%
2012 88.348.793 14.55%
2013 82.749.959 -6.77%
2014 79.334.589 -4.31%
2015 128.272.778 38.15%
2016 214.828.535 40.29%
2017 235.136.468 8.64%
2018 312.358.330 24.72%
2019 304.069.754 -2.73%
2020 359.704.042 15.47%
2021 292.831.322 -22.84%
2022 254.794.886 -14.93%
2023 541.110.402 52.91%
2023 454.862.540 -18.96%
2024 475.369.944 4.31%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. Net Profit
Year Net Profit Growth
2004 13.789.758
2005 13.917.590 0.92%
2006 12.954.761 -7.43%
2007 22.297.465 41.9%
2008 39.854.412 44.05%
2009 25.911.986 -53.81%
2010 33.743.606 23.21%
2011 44.776.081 24.64%
2012 50.954.466 12.13%
2013 54.256.733 6.09%
2014 38.138.794 -42.26%
2015 11.882.008 -220.98%
2016 23.599.152 49.65%
2017 38.850.990 39.26%
2018 69.438.286 44.05%
2019 2.542.755 -2630.83%
2020 7.503.976 66.11%
2021 -322.176.629 102.33%
2022 -78.325.489 -311.33%
2023 32.846.514 338.46%
2023 -24.929.391 231.76%
2024 31.080.728 180.21%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2004 0
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. Free Cashflow
Year Free Cashflow Growth
2006 -15.703.377
2007 22.219.816 170.67%
2008 -8.850.179 351.07%
2009 -7.086.261 -24.89%
2010 9.762.926 172.58%
2011 36.012.036 72.89%
2012 -17.935.896 300.78%
2013 13.721.281 230.72%
2014 -28.376.922 148.35%
2015 53.860.850 152.69%
2016 40.572.757 -32.75%
2017 -134.749.030 130.11%
2018 -137.442.151 1.96%
2019 -144.896.618 5.14%
2020 -116.195.452 -24.7%
2021 -366.170.502 68.27%
2022 -120.738.086 -203.28%
2023 -48.491.188 -148.99%
2023 -60.527.432 19.89%
2024 -49.863.033 -21.39%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
2006 9.401.346
2007 23.297.469 59.65%
2008 16.040.749 -45.24%
2009 22.785.851 29.6%
2010 32.232.683 29.31%
2011 46.893.663 31.26%
2012 61.282.912 23.48%
2013 55.081.309 -11.26%
2014 31.048.911 -77.4%
2015 88.950.522 65.09%
2016 77.969.565 -14.08%
2017 -95.194.051 181.91%
2018 -84.149.884 -13.12%
2019 -36.027.044 -133.57%
2020 86.137.577 141.83%
2021 887.777 -9602.61%
2022 40.718.935 97.82%
2023 0 0%
2023 137.017.197 100%
2024 -14.386.645 1052.39%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
2006 25.104.723
2007 1.077.653 -2229.58%
2008 24.890.928 95.67%
2009 29.872.112 16.68%
2010 22.469.757 -32.94%
2011 10.881.627 -106.49%
2012 79.218.808 86.26%
2013 41.360.027 -91.53%
2014 59.425.833 30.4%
2015 35.089.671 -69.35%
2016 37.396.808 6.17%
2017 39.554.979 5.46%
2018 53.292.267 25.78%
2019 108.869.573 51.05%
2020 202.333.029 46.19%
2021 367.058.279 44.88%
2022 161.457.021 -127.34%
2023 48.491.188 -232.96%
2023 197.544.629 75.45%
2024 35.476.388 -456.83%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. Equity
Year Equity Growth
2004 49.319.354
2005 63.739.145 22.62%
2006 76.954.506 17.17%
2007 99.251.972 22.47%
2008 135.958.334 27%
2009 169.620.651 19.85%
2010 206.003.677 17.66%
2011 249.517.877 17.44%
2012 658.976.381 62.14%
2013 702.554.865 6.2%
2014 726.569.836 3.31%
2015 1.283.289.855 43.38%
2016 1.524.442.735 15.82%
2017 1.613.694.018 5.53%
2018 1.243.930.815 -29.73%
2019 1.052.145.952 -18.23%
2020 1.438.904.878 26.88%
2021 932.745.033 -54.27%
2022 2.323.878.932 59.86%
2023 2.339.531.348 0.67%
2023 2.340.545.028 0.04%
2024 2.396.571.263 2.34%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. Assets
Year Assets Growth
2004 57.696.343
2005 76.122.619 24.21%
2006 80.533.796 5.48%
2007 105.999.655 24.02%
2008 145.401.730 27.1%
2009 177.899.806 18.27%
2010 214.683.639 17.13%
2011 261.697.757 17.97%
2012 701.231.357 62.68%
2013 752.395.749 6.8%
2014 799.338.029 5.87%
2015 2.070.197.063 61.39%
2016 2.094.299.877 1.15%
2017 2.737.468.431 23.5%
2018 2.712.341.755 -0.93%
2019 2.694.604.343 -0.66%
2020 3.715.242.196 27.47%
2021 3.690.026.740 -0.68%
2022 3.908.002.277 5.58%
2023 3.872.849.082 -0.91%
2023 3.926.015.273 1.35%
2024 4.014.148.568 2.2%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. Liabilities
Year Liabilities Growth
2004 8.376.988
2005 12.383.474 32.35%
2006 3.579.289 -245.98%
2007 6.747.683 46.96%
2008 9.443.395 28.55%
2009 8.279.154 -14.06%
2010 8.679.961 4.62%
2011 12.179.879 28.74%
2012 42.254.975 71.18%
2013 49.840.883 15.22%
2014 72.768.192 31.51%
2015 786.907.208 90.75%
2016 569.857.142 -38.09%
2017 1.123.774.412 49.29%
2018 1.468.410.939 23.47%
2019 1.642.458.390 10.6%
2020 2.276.337.317 27.85%
2021 2.757.281.706 17.44%
2022 1.584.123.343 -74.06%
2023 1.533.317.734 -3.31%
2023 1.585.470.244 3.29%
2024 1.617.577.303 1.98%

Beijing Bohui Innovation Biotechnology Group Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.23
Net Income per Share
-0
Price to Earning Ratio
-1692.64x
Price To Sales Ratio
5.42x
POCF Ratio
73.53
PFCF Ratio
-44.33
Price to Book Ratio
3.9
EV to Sales
6.29
EV Over EBITDA
50.81
EV to Operating CashFlow
85.32
EV to FreeCashFlow
-51.47
Earnings Yield
-0
FreeCashFlow Yield
-0.02
Market Cap
5,45 Bil.
Enterprise Value
6,33 Bil.
Graham Number
0.39
Graham NetNet
-1.42

Income Statement Metrics

Net Income per Share
-0
Income Quality
-23.02
ROE
-0
Return On Assets
-0
Return On Capital Employed
0.03
Net Income per EBT
-0.04
EBT Per Ebit
0.99
Ebit per Revenue
0.09
Effective Tax Rate
0.23

Margins

Sales, General, & Administrative to Revenue
0.07
Research & Developement to Revenue
0.07
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.49
Operating Profit Margin
0.09
Pretax Profit Margin
0.09
Net Profit Margin
-0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-10.84
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.09
Free CashFlow per Share
-0.15
Capex to Operating CashFlow
2.66
Capex to Revenue
0.2
Capex to Depreciation
1.7
Return on Invested Capital
0.03
Return on Tangible Assets
-0
Days Sales Outstanding
32.5
Days Payables Outstanding
174.48
Days of Inventory on Hand
647.69
Receivables Turnover
11.23
Payables Turnover
2.09
Inventory Turnover
0.56
Capex per Share
0.24

Balance Sheet

Cash per Share
-0,07
Book Value per Share
2,93
Tangible Book Value per Share
1.49
Shareholders Equity per Share
1.71
Interest Debt per Share
1.22
Debt to Equity
0.7
Debt to Assets
0.24
Net Debt to EBITDA
7.05
Current Ratio
1.12
Tangible Asset Value
1,22 Bil.
Net Current Asset Value
-0,45 Bil.
Invested Capital
2795713422
Working Capital
0,12 Bil.
Intangibles to Total Assets
0.29
Average Receivables
0,07 Bil.
Average Payables
0,26 Bil.
Average Inventory
896805975.5
Debt to Market Cap
0.18

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. Dividends
Year Dividends Growth
2013 0
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%

Beijing Bohui Innovation Biotechnology Group Co., Ltd. Profile

About Beijing Bohui Innovation Biotechnology Group Co., Ltd.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. engages in the research and development, production, sale, and after-sale service of diagnostic products in China. It offers GenPlex, a microfluidic automated nucleic acid detection system, immunofluorescence detection products, and human trace element detection products; and chemical analysis products, such as atomic fluorescence spectrometer and photometer, mass spectrometers, chip ion sources, microfluidic flow chemical analysis systems, life sciences related consumables, and ICP spectroscopy. The company was formerly known as Beijing Bohui Innovation Biotechnology Co., Ltd. and changed its name to Beijing Bohui Innovation Biotechnology Group Co., Ltd. in August 2021. Beijing Bohui Innovation Biotechnology Group Co., Ltd. was founded in 2001 and is headquartered in Beijing, China.

CEO
Mr. Zhiwei Shen
Employee
1.961
Address
Zhongguancun Life Science Park
Beijing, 102206

Beijing Bohui Innovation Biotechnology Group Co., Ltd. Executives & BODs

Beijing Bohui Innovation Biotechnology Group Co., Ltd. Executives & BODs
# Name Age
1 Mr. Zhiwei Shen
Chairman of the Board & GM
70
2 Jia Liu
Financial Director
70
3 Mr. Haifeng Dong
Deputy GM, Secretary & Director
70

Beijing Bohui Innovation Biotechnology Group Co., Ltd. Competitors